Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R-Reference-Cited by-同舟云学术

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R

Published:2018-09-26 Issue:10 Volume:93 Page:1245-1253
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Benton Christopher B.¹^ORCID,Khan Maliha¹^ORCID,Sallman David²,Nazha Aziz³,Nogueras González Graciela M.⁴,Piao Jin⁴,Ning Jing⁴,Aung Fleur⁵,Al Ali Najla²,Jabbour Elias¹^ORCID,Kadia Tapan M.¹^ORCID,Borthakur Gautam¹^ORCID,Ravandi Farhad¹,Pierce Sherry¹,Steensma David⁶,DeZern Amy⁷,Roboz Gail⁸,Sekeres Mikkael³,Andreeff Michael¹,Kantarjian Hagop¹^ORCID,Komrokji Rami S.²^ORCID,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Malignant Hematology; H. Lee Moffitt Cancer Center; Tampa Florida

3. Department of Leukemia; Cleveland Clinic; Cleveland Ohio

4. Department of Statistics; The University of Texas MD Anderson Cancer Center; Houston Texas

5. Laboratory Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

6. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston

7. Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore Maryland

8. Joan and Sanford I. Weill Department of Medicine; Weill Cornell Medical; New York New York

Funder

MD Anderson Moon Shot

MDS Clinical Research Consortium

Edward P. Evans Foundation

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25234/fullpdf

Reference33 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood.,2016

2. Understanding the myelodysplastic syndromes;Kouides;Oncologist,1997

3. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

4. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology;Greenberg;J Natl Compr Canc Netw.,2017

5. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood.,1997

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelodysplastic Syndrome;Comprehensive Hematology and Stem Cell Research;2024

2. The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score;Cancers;2023-07-11

3. Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS);Current Oncology;2023-06-27

4. Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-08

5. The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition;American Society of Clinical Oncology Educational Book;2023-06